NASDAQ •
Healthcare •
Drug Manufacturers - General •
Quote as of 05/15/2026 16:00
Company Profile
IndustryDrug Manufacturers - General
SectorHealthcare
ExchangeNASDAQ
Market Capitalization29,433 mln
Float147 mln
Earnings Date07/29/2026
EPS
9.29
Strong
P / E
20.77
Premium valuation
Piotroski F-Score
4
/ 9
Borderline
Beneish M-Score
-2.68
Likely reliable
1-Year Forecast
217
Modest upside
Relative Strength
80
/ 100
Strongly outperforming
Business Description
Founded in 1978 and based in Cambridge, Massachusetts, Biogen researches, develops, and sells treatments for serious neurological and rare diseases across the United States, Europe, Asia, and other global markets. Its portfolio includes medicines for conditions such as multiple sclerosis, Alzheimer's disease, spinal muscular atrophy, and several blood and autoimmune disorders. The company also works with a broad network of partners, including Eisai, Genentech, Ionis Pharmaceuticals, and Samsung Bioepis, to advance new therapies and expand its range of treatments.
